This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Esophageal Cancer - Multimodality Therapy

February 9, 2023
To understand the shift toward nonsurgical management of esophageal cancer, researchers set out to determine the long-term quality of life (QOL) after esophagectomy. This study found that, in esophagectomy patients surviving more than three years, QOL did not differ significantly from the normative population reference values.
August 12, 2021
Although the standard of care in the West for regionally advanced esophageal cancer entails induction therapy, this is routinely not the case in China. This randomized trial involving over 450 randomized participants to induction therapy (vinorelbine, cisplatin, 40 Gy RT) followed by resection vs resection alone.
August 22, 2019
In this multiinstitutional retrospective study, administration of adjuvant chemotherapy for patients with persistent nodal disease after induction therapy and esophagectomy was associated with improved survival.
January 23, 2019
Stiles and colleagues evaluated outcomes for patients with esophageal cancer undergoing surgical resection after either neoadjuvant chemoradiation or preoperative chemotherapy without radiation.
April 13, 2018
This retrospective analysis of salvage esophagectomy after definitive chemoradiotherapy in 308 patients identified increased mortality and morbidity associated with squamous histology and radiation dose >55 Gy.  Survival at three years was 34%.
November 23, 2016
The authors queried the NCDB to compare outcomes for patients undergoing induction chemotherapy vs chemoradiotherapy followed by resection for esophageal cancer.  The vast majority received chemoradiotherapy (87.5%), which was associated with a better pCR rate and a lower positive margin rate than chemotherapy.   30 and 90-day mortality rates were si
December 24, 2015
Whether postoperative adjuvant therapy for node-positive residual disease after induction therapy and resection for esophageal cancer is unknown.  This single institution study identified 101 node positive patients among 764 treated with induction therapy and surgery during 2000-2012.  45 of 101 patients who underwent adjuvant therapy, primarily chem
September 16, 2015
The 6th and 7th versions of the AJCC staging system were compared for their prognostic accuracy for patients with esophagogastric adenocarcinomas using an institutional database.  The 7th edition system was significantly more accurate in groups undergoing MIE, induction therapy, and overall.
July 23, 2015
This multicenter retrospective study evaluated the efficacy of salvage esophagectomy after definitive chemoradiotherapy compared to planned esophagectomy after induction chemoradiotherapy.  Operative mortality was similarly high in both groups (8.4% vs 9.3%).  Anastomotic leak was higher after salvage esophagectomy (17.2% vs 10.7%).  3-year survival
January 10, 2015
The authors retrospectively analyzed pathologic response rates and their relation to the interval between completion of induction therapy and esophagectomy for esophageal cancer in 88 patients.  Complete response rates increased from 12.5% to 40.9% among quartiles as the interval increased from <45 days to >63 days.  There was no increase in mo